ArticleInfectious diseases and therapy2024
Systematic Literature Review on the Incidence of Herpes Zoster in Populations at Increased Risk of Disease in the EU/EEA, Switzerland, and the UK.
Article in Infectious diseases and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07243236 ("Assessment of the Impact of Vaccine Funding by the National Health Insurance on Vaccination Coverage Among Patients Targeted by Current Vaccination Recommendations and Followed in Outpatient Consultations in Ile-de-France Region in France""), which is not on this map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
"Assessment of the Impact of Vaccine Funding by the National Health Insurance on Vaccination Coverage Among Patients Targeted by Current Vaccination Recommendations and Followed in Outpatient Consultations in Ile-de-France Region in France""
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Current advances in the epidemiology, risk factors, prevention, management, and long-term outcomes of herpes zoster and post-herpetic neuralgia.Frontiers in microbiology · 2026Pooled it
- Hot topics and trends in acupuncture for herpes zoster from 2015 to 2025: a bibliometric and knowledge graph analysis.Frontiers in medicine · 2026Pooled it
- A systematic review and meta-analysis of herpes zoster risk in adults with immunocompromised conditions and autoimmune diseases in Asia-Pacific.Human vaccines & immunotherapeutics · 2025Pooled it
- Herpes zoster vaccination in inflammatory bowel disease: Evidence, guidelines, and reality.World journal of virology · 2026Review
- Observational
- Varicella zoster virus infection.Nature reviews. Disease primers · 2026Review
- Unlocking herpes zoster vaccination value in Finland: return on investment and actuarial model.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Association of Chronic Diseases With Herpes Zoster in China: A Nationwide Population-Based Survey.Health care science · 2026Article
- Herpes Zoster in Patients Treated with JAK Inhibitors for Immune-Mediated Inflammatory Diseases: Incidence, Associated Factors and Vaccination Uptake in a Real-World Cohort.Journal of clinical medicine · 2026Article
- Progressive Improvements with Repeated High-Concentration Capsaicin Patch: Real-World Data from the Retrospective CASPAR German Pain e-Registry Study in Postherpetic Neuralgia.Dermatology and therapy · 2026Article
- Herpes Zoster in Hematological Disorders: Pathogenesis, Risk Stratification, and Emerging Strategies for Prevention and Immunization.European journal of haematology · 2026Review
- Article
- Herpes zoster burden in a private healthcare setting of Argentina.Frontiers in public health · 2026Article
- Infectious diseases, infection control, vaccines and long-term care: an European interdisciplinary Council on ageing consensus document.Aging clinical and experimental research · 2025Review
- Modeling the herpes zoster disease burden and its potential health impact on older adults >50 years of age in Brazil.Human vaccines & immunotherapeutics · 2025Article
- Vaccination Against Herpes Zoster in Adults: Current Strategies in European Union Countries.Vaccines · 2025Review
- Herpes zoster as risk factor for dementia: a matched cohort study over 20 years in a 10-million population in Italy.The journal of prevention of Alzheimer's disease · 2025Article
- Prevalence of VZV Reactivation and Effectiveness of Vaccination with Recombinant Adjuvanted Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Recipients-A Single-Center Analysis.Infectious disease reports · 2025Article
- No Evidence for a Causal Association Between Depression and Herpes Zoster or Post-Herpetic Neuralgia: A Mendelian Randomization Study.Journal of pain research · 2025Article
- Psychiatric Disorders and Their Impact on Herpes Zoster Incidence: Five Years of Data from Turkiye.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOlder adults and patients with underlying conditions such as immunocompromised (IC) populations (e.g., due to medical conditions or immunosuppressive medication) are at increased risk for herpes zoster (HZ). The first HZ recombinant vaccine for IC patients was approved in 2020. Limited evidence exists to inform decision-makers on HZ incidence in high-risk patients in Europe. This systematic literature review (SLR) assessed HZ incidence across 14 high-risk populations in the European Union/European Economic Area, Switzerland, and the United Kingdom.
methodsAn SLR (Embase, Medline, 2002-2022, observational studies) was performed to identify HZ incidence (i.e., primary outcomes: rate or cumulative; secondary: relative incidence) in type 1 and 2 diabetes mellitus (DM); chronic obstructive pulmonary disease and asthma; depression; rheumatic disorders (RD); multiple sclerosis (MS); inflammatory bowel diseases (IBD); psoriasis; lupus; human immunodeficiency virus (HIV); solid organ transplantation (SOT); solid organ malignancy (SOM); hematologic malignancy (HM); and stem cell transplantation (SCT).
resultsOf 776 unique records screened, 59 studies were included (24 reported incidence rate per 1000 person-years; two, cumulative incidence per 1000 persons; and 33, relative incidence). The highest incidence rates were reported for SOT (12.1-78.8) and SCT (37.2-56.1); HM (2.9-32.0); RD (0.41-21.5); lupus (11.0-16.5); IC mixed population (11.3-15.5); HIV/AIDS (11.8-13.0); chronic respiratory diseases (4.7-11.4); SOM (8.8-11.0); IBD (7.0-10.8); DM (4.3-9.4); depression (7.2-7.6); MS (5.7-6.3); and psoriasis (5.3-6.1). In many high-risk populations, HZ incidence was higher for older age groups, women, and some treatments.
conclusionsThe HZ incidence rate in Europe increased with age and varied across high-risk populations, with high rates for solid organ and stem cell transplants, cancer, and rheumatoid arthritis. Most studies were retrospective with methodological differences affecting generalizability and comparability. Future studies should stratify data by IC population, age, sex, severity, medication, and study timeframe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.